drugset / Trial / NCT07332000
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Timeline
- Start
- 2025-10-30
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valacyclovir | Unknown | — | Oral |
| Subject | aglatimagene besadenovec | Unknown | — | Other |